JP2022529370A5 - - Google Patents
Info
- Publication number
- JP2022529370A5 JP2022529370A5 JP2021562810A JP2021562810A JP2022529370A5 JP 2022529370 A5 JP2022529370 A5 JP 2022529370A5 JP 2021562810 A JP2021562810 A JP 2021562810A JP 2021562810 A JP2021562810 A JP 2021562810A JP 2022529370 A5 JP2022529370 A5 JP 2022529370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- item
- group
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837829P | 2019-04-24 | 2019-04-24 | |
| US62/837,829 | 2019-04-24 | ||
| PCT/US2020/029465 WO2020219639A1 (en) | 2019-04-24 | 2020-04-23 | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529370A JP2022529370A (ja) | 2022-06-21 |
| JP2022529370A5 true JP2022529370A5 (https=) | 2023-04-04 |
| JP7470713B2 JP7470713B2 (ja) | 2024-04-18 |
Family
ID=70740750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562810A Active JP7470713B2 (ja) | 2019-04-24 | 2020-04-23 | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11155549B2 (https=) |
| EP (1) | EP3958969B1 (https=) |
| JP (1) | JP7470713B2 (https=) |
| AR (1) | AR118768A1 (https=) |
| CA (1) | CA3135383A1 (https=) |
| ES (1) | ES2974577T3 (https=) |
| HR (1) | HRP20240346T1 (https=) |
| HU (1) | HUE066802T2 (https=) |
| PL (1) | PL3958969T3 (https=) |
| TW (1) | TW202106682A (https=) |
| WO (1) | WO2020219639A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| TW202106681A (zh) * | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| US20210212962A1 (en) * | 2020-01-13 | 2021-07-15 | Sol-Gel Technologies Ltd. | Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases |
| CA3216017A1 (en) * | 2021-04-22 | 2022-10-27 | Shengjian Huang | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20070179125A1 (en) | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| CN104011050A (zh) | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (https=) * | 2014-08-21 | 2018-03-31 | ||
| ES2753159T3 (es) | 2015-05-28 | 2020-04-07 | Theravance Biopharma R&D Ip Llc | Compuestos de naftiridina como inhibidores de quinasa JAK |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2020108516A1 (zh) | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020108613A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| CN113372364B (zh) | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
| CN113372351A (zh) | 2020-03-10 | 2021-09-10 | 明慧医药（杭州）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
-
2020
- 2020-04-23 PL PL20726591.9T patent/PL3958969T3/pl unknown
- 2020-04-23 ES ES20726591T patent/ES2974577T3/es active Active
- 2020-04-23 HR HRP20240346TT patent/HRP20240346T1/hr unknown
- 2020-04-23 TW TW109113575A patent/TW202106682A/zh unknown
- 2020-04-23 WO PCT/US2020/029465 patent/WO2020219639A1/en not_active Ceased
- 2020-04-23 JP JP2021562810A patent/JP7470713B2/ja active Active
- 2020-04-23 AR ARP200101152A patent/AR118768A1/es unknown
- 2020-04-23 CA CA3135383A patent/CA3135383A1/en active Pending
- 2020-04-23 HU HUE20726591A patent/HUE066802T2/hu unknown
- 2020-04-23 US US16/856,280 patent/US11155549B2/en active Active
- 2020-04-23 EP EP20726591.9A patent/EP3958969B1/en active Active
-
2021
- 2021-09-27 US US17/448,922 patent/US11845747B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529370A5 (https=) | ||
| JP2022529371A5 (https=) | ||
| JP2023022227A (ja) | 肝線維症を治療する方法 | |
| AU2020305979B2 (en) | Method for treating idiopathic pulmonary fibrosis | |
| CN102497864B (zh) | 用于预防或治疗由化疗诱发的疼痛的σ配体 | |
| JP2009536659A (ja) | 血液疾患の治療法 | |
| JP2020519606A5 (https=) | ||
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2022533182A5 (https=) | ||
| RU2017131354A (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| JP5882296B2 (ja) | 創傷の予防及び治療のための組成物及び方法 | |
| WO2021000785A1 (zh) | 作为詹纳斯激酶1选择抑制剂的吡咯并[2,3-b]吡啶衍生物 | |
| CN1260784A (zh) | 作为pdeiv和tnf抑制剂的喹啉衍生物 | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| EP2716639A1 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| CN114072401A (zh) | 作为irak4和btk多靶点抑制剂的噁唑类化合物 | |
| RU2014143232A (ru) | Соединения для применения в лечении нейробластомы, саркомы юинга или рабдомиосаркомы | |
| EP4367107A1 (en) | Novel compounds as inhibitors of pcsk9 | |
| JP2006502168A5 (https=) | ||
| JP6363192B2 (ja) | トリグリセリド、総コレステロール、及び低密度リポタンパク質の血中濃度を低減する方法 | |
| US9796722B1 (en) | Hepatitis B viral assembly effectors |